托珠单抗在新型冠状病毒治疗中的临床药学指引  

Pharmacological recommendations on tocilizumab for the treatment of COVID-19

作　　者：张建红[1] 朱立勤[2] 刘子艳[1] 刘玉媛[1] ZHANG Jian-hong;ZHU Li-qin;LIU Zi-yan;LIU Yu-yuan(Department of Pharmacy,Tianjin Fourth Central Hospital,Tianjin 300140,China;Department of Pharmacy,Tianjin First Central Hospital,Tianjin 300192,China)

机构地区：[1]天津市第四中心医院药剂科,天津300140 [2]天津市第一中心医院药剂科,天津300192

出　　处：《中国医院药学杂志》2020年第10期1077-1080,共4页Chinese Journal of Hospital Pharmacy

摘　　要：2019年12月末国在内外相继出现新型冠状病毒肺炎(corona virus disease-19,COVID-19)病例。有专家指出COVID-19感染者病情的突然加重可能和“细胞因子风暴”(炎症风暴)有关,目前并无针对于此的特效药。托珠单抗为IL-6拮抗剂,很可能阻断细胞因子风暴进而阻止COVID-19患者向重症转变。但因证据有限,临床工作者在实践中面临着许多问题,如缺乏托珠单抗在一般和特殊人群中的详细用药指导,推荐方案的依据不明确等。本文就该药物的基本信息、国内外研究现状、相互作用、不良反应等方面进行概述,以期为临床用药提供参考。At the end of December 2019,successive cases of novel corona virus disease-19(COVID-19)occured at home and abroad.Some experts point out that the sudden aggravation of COVID-19 infected patients may be related to the“cytokine storm”(inflammatory storm),and there is no specific drug for the condition.Tocilizumab is an IL-6 antagonist,which is likely to block the cytokine storm and then prevent the transition to severe disease in COVID-19 patients.However,because of limited evidence,clinicians face many problems in practice,such as the lack of detailed medication guidance for tocilizumab in general and special populations,and the unclear basis for the recommended regimen.In this paper,the basic information,domestic and foreign research status,interaction,adverse reactions and other aspects of the drug are summarized in order to provide a reference for clinical medication.

关 键 词：托珠单抗 新型冠状病毒 细胞因子风暴 

分 类 号：R954[医药卫生—药学]